Can Targeting the Androgen Receptor Help in Treating Cancer?
Yes, targeting the AR is a critical therapeutic strategy, especially in prostate cancer. Drugs such as enzalutamide and abiraterone have been developed to inhibit AR signaling. Enzalutamide works by blocking AR binding to androgens, while abiraterone inhibits androgen production. These treatments can delay disease progression and improve survival, although resistance eventually develops in many patients.
